Literature DB >> 19474675

Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial.

Reza Asari1, Oskar Koperek, Christian Scheuba, Philipp Riss, Klaus Kaserer, Martha Hoffmann, Bruno Niederle.   

Abstract

OBJECTIVE: To determine risk factors for presence of lymph node or distant metastases in patients with follicular thyroid cancer (FTC) at the time of diagnosis and whether there is a relationship between the type of tumor invasion and metastases. SUMMARY BACKGROUND DATA: FTC often presents distant metastases at the initial diagnosis. As distant metastases are independent prognostic factors in a patient's survival, determination of clinicopathologic characteristics for patients who are at higher risk for developing metastases is of greater clinical importance.
METHODS: The prognostic significance of gender (male vs. female), age (<or=40 years vs. <40 years), tumor size (<or=40 mm vs. >40 mm), number of lesions (uni- vs. multifocality), type of invasion (minimally invasive vs. widely invasive), and oncocytic changes (with vs. without) were analyzed in 207 patients, according to presence of lymph node and distant metastases at the time of initial surgery. According to the type of invasion, the carcinoma-specific survival and the disease-free survival of minimally invasive (MI) and widely invasive (WI) FTC were estimated and compared.
RESULTS: None of the 127 patients with MI growth presented with lymph node metastases but 9.4% distant metastases. Overall risk factors for the presence of lymph node metastases at the initial diagnosis were multifocality (P = 0.02) and widely invasion (P = 0.0001) and for distant metastases age >45 years (P = 0.007), tumor size larger than 40 mm (P = 0.03) and widely invasion (P = 0.0001).WI-FTC patients show larger tumors (P = 0.0001), older age (P = 0.0001), and are presented more frequently in recurrent goiter disease (P = 0.0001). The estimated 10 years carcinoma-specific survival and disease-free survival for MI-tumors were significantly better than for WI-tumors (P = 0.0001).
CONCLUSIONS: Total thyroidectomy is recommended in all patients with FTC because of early distant metastases. Patients with WI-FTC need a more aggressive surgical treatment because of higher tendency for lymph node metastases. MI-FTC has an excellent prognosis with no sign of lymph node metastases, which emphasizes a limited need for nodal surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19474675     DOI: 10.1097/SLA.0b013e3181a77b7b

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  26 in total

1.  [Current TNM system of the UICC/AJCC : the prognostic significance for differentiated thyroid carcinoma].

Authors:  M Stratmann; C Sekulla; H Dralle; M Brauckhoff
Journal:  Chirurg       Date:  2012-07       Impact factor: 0.955

Review 2.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

3.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

4.  Prognostic Impact of Further Treatments on Distant Metastasis in Patients With Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting.

Authors:  Yu-Mi Lee; Yi Ho Lee; Dong Eun Song; Won Bae Kim; Tae-Yon Sung; Jong Ho Yoon; Ki-Wook Chung; Suck Joon Hong
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

Review 5.  [Individualization of the surgical procedure in response to overdiagnosis and overtreatment in differentiated thyroid carcinomas].

Authors:  J I Staubitz; T J Musholt
Journal:  Pathologe       Date:  2019-12       Impact factor: 1.011

Review 6.  [Minimally invasive follicular thyroid carcinoma : Not always total thyroidectomy].

Authors:  M Hermann; K Tonninger; F Kober; E-M Furtlehner; A Schultheis; N Neuhold
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

7.  Hemithyroidectomy for low-risk follicular carcinoma of the thyroid: results from a regional hospital.

Authors:  Tam-Lin Chow; Susanna Wai-Yin Tam; Chi-Yee Choi; Wilson Wai-Yin Kwan
Journal:  Singapore Med J       Date:  2017-12-07       Impact factor: 1.858

8.  Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer.

Authors:  David F Schneider; Dawn Elfenbein; Ricardo V Lloyd; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-08-05       Impact factor: 5.344

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.